Published Date: 16 Feb 2024
Features, news, and analysis on matters pertaining to cancer.
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
NIH research cuts leave cancer patient facing hard choice
2.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
3.
Year in Review: Multiple Myeloma
4.
Study reveals that older women frequently receive an incorrect breast cancer diagnosis.
5.
Promising for Monitoring and Diagnosis of AD is the finger-prick test.
1.
Unveiling the Hidden Benefits of Lymphedema Treatment
2.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
3.
Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making
4.
Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership
5.
Understanding Apoplexy: Symptoms, Causes, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation